FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Chung Christine 2. Issuer Name and Ticker or Trading Symbol FIBROGEN INC [ FGEN ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP, China Operations
(Last)         (First)         (Middle)
C/O FIBROGEN, INC., 409 ILLINOIS ST.
3. Date of Earliest Transaction (MM/DD/YYYY)
3/6/2020
(Street)
SAN FRANCISCO, CA 94158
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  3/6/2020    F    10126 (1) D $39.71  122518  D   
Common Stock  3/17/2020    A    40000 (2) A $0.00  162518  D   
Common Stock  3/18/2020    M    400  A $25.40  162918  D   
Common Stock  3/18/2020    S    905 (3) D $23.69 (4) 162013  D   
Common Stock  3/18/2020    S    1500 (3) D $24.56 (5) 160513  D   
Common Stock  3/18/2020    S    1500 (3) D $25.68 (6) 159013  D   
Common Stock  3/19/2020    M    7345  A $25.40  166358  D   
Common Stock  3/19/2020    S    300 (3) D $23.93 (7) 166058  D   
Common Stock  3/19/2020    S    830 (3) D $25.32 (8) 165228  D   
Common Stock  3/19/2020    S    6215 (3) D $26.08 (9) 159013  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $26.41  3/17/2020    A     66250       (10) 3/17/2030  Common Stock  66250  $0.00  66250  D   
Stock Option (Right to Buy)  $25.40  3/18/2020    M        400    (11) 3/8/2027  Common Stock  400  $0.00  42064  D   
Stock Option (Right to Buy)  $25.40  3/19/2020    M        7345    (11) 3/8/2027  Common Stock  7345  $0.00  34719  D   

Explanation of Responses:
(1)  Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.
(2)  Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on March 6, 2021, and the remainder vests in equal amounts quarterly thereafter for the following three years.
(3)  Shares sold pursuant to a 10b5-1 plan.
(4)  The shares were sold at prices ranging from $23.10 to $24.07. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
(5)  The shares were sold at prices ranging from $24.13 to $25.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
(6)  The shares were sold at prices ranging from $25.26 to $26.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
(7)  The shares were sold at prices ranging from $23.50 to $24.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
(8)  The shares were sold at prices ranging from $24.71 to $25.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
(9)  The shares were sold at prices ranging from $25.71 to $26.525. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
(10)  Twenty-five percent of the shares subject to the option vests on March 1, 2021, and the remainder vests in equal amounts quarterly thereafter for the following three years.
(11)  Twenty-five percent of the shares subject to the option vests on March 1, 2018, and the remainder vests in equal amounts quarterly thereafter for the following three years.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Chung Christine
C/O FIBROGEN, INC.
409 ILLINOIS ST.
SAN FRANCISCO, CA 94158


SVP, China Operations

Signatures
/s/ Dorothy Pacini, Attorney-in-fact 3/19/2020
**Signature of Reporting Person Date
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more FibroGen Charts.
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more FibroGen Charts.